Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

LiF@SiO2 nanocapsules for controlled lithium release and osteoarthritis treatment

Abstract

Electrolytes can be taken orally or intravenously as supplements or therapeutics. However, their therapeutic window may exceed the serum toxicity threshold, making systemic delivery a poor option. Local injection is also not adequate due to rapid diffusion of electrolytes. Here, we solved this issue with a nanocapsule technology, comprising an electrolyte nanocrystal as the drug filling and a silica sheath to regulate drug release rates. In particular, we prepared LiF@SiO2 nanocapsules and investigated their potential as a delivery system for lithium, which was shown in recent studies to be an effective therapeutic agent for osteoarthritis (OA). We demonstrated that LiF@SiO2 can extend lithium release time from minutes to more than 60 h. After intraarticular (i.a.) injection into a rat OA model, the nanocapsules reduced the Osteoarthritis Research Society International (OARSI) score by 71% in 8 weeks while inducing no systemic toxicity. Our study opens new doors for improved delivery of electrolyte therapeutics, which have rarely been studied in the past.

This is a preview of subscription content, log in to check access.

References

  1. [1]

    Cho, K.; Wang, X.; Nie, S. M.; Chen, Z. G.; Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14, 1310–1316.

  2. [2]

    Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3, 16–20.

  3. [3]

    Phiel, C. J.; Klein, P. S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 789–813.

  4. [4]

    Corbella, B.; Vieta, E. Molecular targets of lithium action. Acta Neuropsychiatr. 2003, 15, 316–340.

  5. [5]

    Ryves, W. J.; Harwood, A. J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 2001, 280, 720–725.

  6. [6]

    Geddes, J. R.; Burgess, S.; Hawton, K.; Jamison, K.; Goodwin, G. M. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiat. 2004, 161, 217–222.

  7. [7]

    Geller, B.; Luby, J. Child and adolescent bipolar disorder: A review of the past 10 years. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36, 1168–1176.

  8. [8]

    Hui, W.; Litherland, G. J.; Jefferson, M.; Barter, M. J.; Elias, M. S.; Cawston, T. E.; Rowan, A. D.; Young, D. A. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology 2010, 49, 2043–2053.

  9. [9]

    Minashima, T.; Zhang, Y.; Lee, Y.; Kirsch, T. Lithium protects against cartilage degradation in osteoarthritis. Arthritis Rheumatol. 2014, 66, 1228–1236.

  10. [10]

    Thompson, C. L.; Wiles, A.; Poole, C. A.; Knight, M. M. Lithium chloride modulates chondrocyte primary cilia and inhibits hedgehog signaling. Faseb J. 2016, 30, 716–726.

  11. [11]

    Lawrence, R. C.; Felson, D. T.; Helmick, C. G.; Arnold, L. M.; Choi, H.; Deyo, R. A.; Gabriel, S.; Hirsch, R.; Hochberg, M. C.; Hunder, G. G. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the united states. Arthritis Rheum. 2008, 58, 26–35.

  12. [12]

    Hunter, D. J.; Neogi, T.; Hochberg, M. C. Quality of osteoarthritis management and the need for reform in the US. Arthrit. Care Res. 2011, 63, 31–38.

  13. [13]

    Thompson, C. L.; Yasmin, H.; Varone, A.; Wiles, A.; Poole, C. A.; Knight, M. M. Lithium chloride prevents interleukin-1β induced cartilage degradation and loss of mechanical properties. J. Orthop. Res. 2015, 33, 1552–1559.

  14. [14]

    Oruch, R.; Elderbi, M. A.; Khattab, H. A.; Pryme, I. F.; Lund, A. Lithium: A review of pharmacology, clinical uses, and toxicity. Eur. J. Pharmacol. 2014, 740, 464–473.

  15. [15]

    Finley, P. R.; Warner, M. D.; Peabody, C. A. Clinical relevance of drug interactions with lithium. Clin. Pharmacokinet. 1995, 29, 172–191.

  16. [16]

    Timmer, R. T.; Sands, J. M. Lithium intoxication. J. Am. Soc. Nephrol. 1999, 10, 666–674.

  17. [17]

    Evans, C. H.; Kraus, V. B.; Setton, L. A. Progress in intra-articular therapy. Nat. Rev. Rheumatol. 2014, 10, 11–22.

  18. [18]

    Gerwin, N.; Hops, C.; Lucke, A. Intra-articular drug delivery in osteoarthritis. Adv. Drug Deliv. Rev. 2006, 58, 226–242.

  19. [19]

    Zhang, W.; Ouyang, H. W.; Dass, C. R.; Xu, J. K. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res. 2016, 4, 15040.

  20. [20]

    Brown, T. J.; Laurent, U. B.; Fraser, J. R. Turnover of hyaluronan in synovial joints: Elimination of labelled hyaluronan from the knee joint of the rabbit. Exp. Physiol. 1991, 76, 125–134.

  21. [21]

    Schaafsma, G. Calcium in extracellular fluid: Homeostasis. In Calcium in Human Biology. Nordin, B. E. C., Eds.; Springer: London, 1988; pp 241–259.

  22. [22]

    Cox, S. W.; Eley, B. M.; Kiili, M.; Asikainen, A.; Tervahartiala, T.; Sorsa, T. Collagen degradation by interleukin-1β-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases. Oral Dis. 2006, 12, 34–40.

  23. [23]

    Ning, B.; Wang, P.; Pei X. H.; Kang, Y. Q.; Song, J.; Wang, D. H.; Zhang, W. L.; Ma, R. X. Dual function of β-catenin in articular cartilage growthand degeneration at different stages of postnatal cartilage development. Int. Orthop. 2012, 36, 655–664.

  24. [24]

    Marshall, K. W.; Chan, A. D. M. Arthroscopic anterior cruciate ligament transection induces canine osteoarthritis. J. Rheumatol. 1996, 23, 338–343.

  25. [25]

    Altman, R. D.; Manjoo, A.; Fierlinger, A.; Niazi, F.; Nicholls, M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: A systematic review. BMC Musculoskel. Dis. 2015, 16, 321.

  26. [26]

    Young, W. Review of lithium effects on brain and blood. Cell Transplant. 2009, 18, 951–975.

Download references

Acknowledgements

This work was supported by two National Institutes of Health grants (R01EB022596, J. X., and R01NS093314, F. W. and J. X.), one Congressionally Directed Medical Research Programs grant (CA140666, J. X.), one National Science Foundation grant (NSF1552617, J. X.), one University of Georgia–Georgia Regents University seed grant (J. X.), and one University of Georgia Postdoc Research Award grant (H. M. C.). We also thank the National Natural Science Fund of China (No. 81760326, L. Z.), the Distinguished Young Scholars Program of Guangxi Medical University (L. Z.), the Guangxi Science and Technology Major Project (Guike AA17204085, L. Z.), and the Guangxi Scientific Research and Technological Development Foundation (GuikeAB16450003, L. Z.).

Author information

Correspondence to Li Zheng or Jin Xie.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Todd, T., Lu, Z., Zhao, J. et al. LiF@SiO2 nanocapsules for controlled lithium release and osteoarthritis treatment. Nano Res. 11, 5751–5760 (2018). https://doi.org/10.1007/s12274-018-2061-5

Download citation

Keywords

  • osteoarthritis
  • controlled release
  • hyaluronic acid
  • lithium
  • anti-inflammation